BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced three ongoing Phase 1 clinical trials, with clinical data readouts from each program expected in 2026Cash runway expected to fund BBOT operations into 2028Appointed industry veteran Uneek Mehra as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BridgeBi ...